8 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
Folate-Target Nanodevices To Activated Macrophages For Rheumatoid Arthritis (FOLSMART)
Date du début: 1 janv. 2016, Date de fin: 31 déc. 2019,
FOLSMART will bring to phase I clinical trials novel folate-based nanodevices (FBN) for the treatment of rheumatoid arthritis (RA). These nanodevices for folic acid (FA)-mediated targeting of activated macrophages showed improved clinical scores in a mouse model of RA when compared to methotrexate (MTX), a first-line drug therapy for the treatment of RA. In this way, FBN will be benchmarked agains ...
Voir le projet
8
Participants partenaires
TERMINÉ
Functional materials for fast diagnosis of wound infection (InFact)
Date du début: 1 janv. 2014, Date de fin: 31 déc. 2017,
"Early detection of an incipient wound infection is a challenge for the attending physician , since its early diagnosis allows the timely initiation of treatment, thus reducing the severity of the disease . Currently, however, wound infection is not diagnosed until becoming already evident. As a consequence, the treatment of the patient is further complicated and more likely to have a negative ou ...
Voir le projet
11
Participants partenaires
TERMINÉ
Tumor Infiltrating Myeloid Cell Compartment (TIMCC)
Date du début: 1 nov. 2012, Date de fin: 31 oct. 2016,
"The ITN TIMCC brings together eight expert teams from different disciplines within Immunology, Genetics and Oncology, to provide substantive and methodological training in the analysis of the role of the Tumor Infiltrating Myeloid Cell Compartment (TIMCC) of the innate immune system. Leukocytes recruited to (pre)malignant tissues are mainly myeloid cells. They can either prevent or functionally c ...
Voir le projet
8
Participants partenaires
TERMINÉ
Prolonged inhibition of semaphorine3a pathway via a bio-degradable implant towards a better therapy for visual sensory impairments (VISION)
Date du début: 1 sept. 2012, Date de fin: 31 août 2016,
"The visual pathway is a component of the central nervous system (CNS) and therefore is not regenerative. Acute optic nerve injury, ischemic optic neuropathy and glaucoma are conditions that initially lead to partial blindness and eventually could lead to total blindness. Extensive neuron and retinal ganglion cells (RGC) death is evidenced in these pathologies. Semaphorin 3A (Sema3A) is a cell sec ...
Voir le projet
5
Participants partenaires
TERMINÉ
Novel approaches for prevention and degeneration of pathogenic bacteria biofilms formed on medical devices e.g. catheters (NOVO)
Date du début: 1 janv. 2012, Date de fin: 31 déc. 2014,
"Biofilms are bacterial communities encased in a self-produced hydrated polymeric matrix. An important characteristic of microbial biofilms is their innate resistance to the immune system and susceptibility to antibiotics. This resistance has made microbial biofilms a common cause of medical infections, and difficult-to-treat infections caused by colonized foreign bodies.The NOVO project aims at d ...
Voir le projet
12
Participants partenaires
TERMINÉ
Folate-based nanobiodevices for integrated diagnosis/therapy targeting chronic inflammatory diseases (NANOFOL)
Date du début: 1 déc. 2009, Date de fin: 30 nov. 2013,
"NANOFOL proposes to develop a new diagnostic/therapy approach using folate based nanobiodevices (FBN) able to provide a new type of cost efficient treatment for chronic inflammatory diseases such as Atherosclerosis and Rheumatoid Arthritis with low side effects that will constitute a more advantageous solution than current therapies. NANOFOL will achieve all that by fulfilling the following obje ...
Voir le projet
14
Participants partenaires
TERMINÉ
Selected peptides as drug candidates directed to pain and neurodegeneration (PEP2BRAIN)
Date du début: 1 mars 2009, Date de fin: 28 févr. 2013,
...nd ADME/toxicity characteristics for our lead molecule. This requires technology, knowledge and innovation transfer since the inventors and Bioalvo are unable to perform this endeavour on their own. Synovo, a German company expert in ADME/tox tests and the University of Tuebingen, with a group expert in Medicinal Chemistry, joined Bioalvo and the Universities of Lisbon and Girona to transfer all ...
Voir le projet
5
Participants partenaires
TERMINÉ
Novel anti-inflammatory compounds for autoimmune diseases (KINACEPT)
Date du début: 1 déc. 2008, Date de fin: 30 nov. 2010,
"The consortium has a lead series of p38 inhibitors with unusual anti-inflammatory properties. The drug leads were originally elaborated as a potential therapy for inflammatory bowel disease, however, the potency of the compounds and their general anti-inflammatory mode of action has raised the possibility of studying their utility in other diseases including rheumatoid arthritis. In addition ...
Voir le projet